Amplia today announced that following the Safety Review Committee's assessment that the AMP945 dose used in Cohort 2 of the ACCENT trial was safe and well tolerated, dosing of the first patient in Cohort 3 has commenced.
Amplia’s CEO and Managing Director Dr Chris Burns commented:
“We are very pleased with the recent progress in the ACCENT trial and moving rapidly to Cohort 3 is the next step in identifying a safe and effective dose to take forward to the Phase 2 stage of the trial. We are extremely grateful to the clinical trial sites for their hard work in progressing the trial so quickly, and to the patients and their loved ones for agreeing to take part in this trial.”
Click here to read today’s ASX release.
